Dr Sharman's latest blog looks at how R-CHOP became established as the most commonly used standard of care for DBLC (i.e. how patients fared better when rituximab was added to the existing CHOP therapy) and what options are available for relapsed DBLC patients.
While not specifically relevant to CLL, it may be of interest due to the discussion on how available options (including bone marrow stem cell transplants) are explored for relapsed blood cancer patients.
cll-nhl.com/2014/01/relapse...
Neil
ASH 2014. Dr. Sharman discusses the biology of our CLL cells
Morphing B-cell leukemia cells into healthy machrophages
BRUIN Study: phase 1/2 study of Pirtobrutinib (formerly Loxo 305) in relapsed or refractory B-cell malignancies 
Mantle Cell Lymphoma...need best treatment options
Diagnosed with Monoclonal B-cell lymphocytosis (MBL) and scared!
